Key Highlights

  • ClearOne (NASDAQ:CLRO) was trading down 11.59% at USD 6.10 on Thursday, November 19, 2026, in intraday market data, implying a prior close near USD 6.90 (calculated), still above the USD 4.00 issue price.
  • The company issued 999,999 shares at USD 4.00 each for USD 3,999,998 of total consideration, completed on November 17, 2026 after agreements signed on November 13, 2026.
  • Gross cash proceeds were about USD 2.756 million, while USD 1,244,458 of Debt owed to First Finance, including accrued interest, was converted into 311,114 shares.
  • Shares outstanding rose to 3,675,411, so the new shares are about 27% of the total, and preliminary pro forma Equity was USD 3.282 million against a USD 2.5 million minimum.

Share Sale and Debt Conversion Lift the Share Count

ClearOne (NASDAQ:CLRO) was trading at USD 6.10, down 11.59%, in intraday market data on Thursday, November 19, 2026. No separate announcement for the move was found, but the company completed a share sale on November 17, 2026. It issued 999,999 shares at USD 4.00 each: 188,885 shares to its largest holder, First Finance, for USD 755,540 in cash, 311,114 shares to First Finance in exchange for USD 1,244,458 of debt, and 500,000 shares to other accredited investors for USD 2,000,000. Gross cash proceeds were about USD 2.756 million, earmarked for Working Capital and general corporate purposes. Because the stock trades well above the issue price, holders may be reacting to dilution and to the gap between those prices.

A Nasdaq Hearing Hangs Over the Listing

The financing is tied to a listing fight. On October 8, 2026, Nasdaq staff determined that ClearOne had not met the USD 2.5 million minimum stockholders' equity requirement and moved to delist its shares. The company requested a hearing on October 14, 2026, which stayed the suspension while a panel considers the case, and a hearing was scheduled for November 17, 2026. ClearOne submitted preliminary, unaudited pro forma equity of USD 3.282 million as of September 30, 2026, a cushion of USD 782,000, or about 31%. It warned that audit adjustments, offering costs and operating losses could reduce that figure, and Nasdaq has not confirmed the deficiency is resolved.

Zero Revenue, Thin Cash and a Pending Merger

ClearOne sold its core audio conferencing operations to Biamp Systems in an asset sale in October 2025. Published coverage of its third-quarter filing reported zero Revenue from continuing operations for the quarter ended September 30, 2026, cash of only USD 18 thousand, a working capital Deficit of USD 663 thousand and going-concern doubt, with figures to be checked against the company filing. The same coverage said a July 1, 2026 Merger agreement with Cortigent and Vivani Medical would give Vivani about 82% pro forma ownership and requires a concurrent public offering of USD 10 million to USD 15 million at USD 4.15 per unit. That deal remains reported and unconfirmed here. With only 3.7 million shares outstanding, a small number of trades can move the price and quoted moves can reverse.

Where Things Stand

It is down mainly because the company has just added shares and the quote sits far above the USD 4.00 price paid by new holders, though no company statement links the two. ClearOne (NASDAQ:CLRO) now has 3,675,411 shares, no Operating Revenue reported and a Nasdaq decision still pending. The equity cushion on a pro forma basis is thin and unaudited. Next markers are the hearing panel's ruling, the final audited equity figure, progress on the reported merger and the 2026 annual report.